Anti-Infective Research Unit est. at Murdoch Childrens
Filed with ASX · · 4 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Approval to Start Phase I/II Diabetic Foot Ulcer Study
- Anti-Infective Portfolio Update and Webinar details
- Pause in trading
- R327 COVID Study Update
- Expansion and Acceleration of Clinical Programs
Later from Recce Pharmaceuticals
- Australian Patent to be Granted for RECCE Anti-Infectives
- JP Morgan Healthcare Conference
- A$6.21m Received from R&D Rebate Payments
- Recce Selects CMAX for Phase I/II UTI Clinical Trial
- Corporate Presentation - WI Emergence 2023
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals